In silico prediction of the lipid-lowering efficacy of the oral PCSK9 inhibitor enlicitide using a mechanistic computational model

Key Points

• Lipid-lowering efficacy was effectively modeled using computational simulations and mechanistic pathways.
• In silico predictions indicated significant efficacy for the oral PCSK9 inhibitor enlicitide in lipid management.
• This analysis utilized a mechanistic computational model to explore lipid-lowering mechanisms and therapeutic potential.
• These findings highlight the promise of computational approaches in predicting drug efficacy and guiding clinical applications.